Search results - ORA - Oxford University Research Archive

1 - 19 of 19

1

Journal article

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.

Zackrisson, B, Aus, G, Bergdahl, S, et al.
2004-04-01

2

Journal article

Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals.

Franks, K, Kancherla, K, Sethugavalar, B, et al.
2011-08-01

3

Journal article

Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.

Low, B, Liong, M, Yuen, K, et al.
2008-04-01

4

Journal article

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

Becker, C, Piironen, T, Pettersson, K, et al.
2000-01-01

5

Journal article

Re: The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease.

Turney, B, Turner, K, Davies, DR, et al.
2005-07-01

6

Journal article

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.

Bruun, L, Ekberg, H, Bjørk, T, et al.
2004-04-01

7

Journal article

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.

Steuber, T, Nurmikko, P, Haese, A, et al.
2002-11-01

8

Journal article

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.

Haese, A, Graefen, M, Steuber, T, et al.
2003-12-01

9

Journal article

Testosterone as a predictor of pathological stage in clinically localized prostate cancer.

Isom-Batz, G, Bianco, F, Kattan, M, et al.
2005-06-01

10

Journal article

Demographic and clinical characteristics of chronic prostatitis: prospective comparison of the University of Sciences Malaysia Cohort with the United States National Institutes of Health Cohort.

Lee, S, Cheah, P, Liong, M, et al.
2007-01-01

11

Journal article

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.

Hugosson, J, Aus, G, Lilja, H, et al.
2003-05-01

12

Journal article

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.

Becker, C, Piironen, T, Pettersson, K, et al.
2003-10-01

13

Journal article

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

Haese, A, Vaisanen, V, Lilja, H, et al.
2005-03-01

14

Journal article

Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.

Cheah, P, Liong, M, Yuen, K, et al.
2003-02-01

15

Journal article

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.

Vickers, A, Wolters, T, Savage, C, et al.
2010-09-01

16

Journal article

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.

Aalamian, M, Tourkova, I, Chatta, G, et al.
2003-11-01

17

Journal article

Re: nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses: C. J. Weight, B. T. Larson, A. F. Fergany, T. Gao, B. R. Lane, S. C. Campbell, J. H. Kaouk, E. A. Klein and A. C. Novick J Urol 2010; 183: 1317-1323.

Patel, N, Sullivan, M, Cranston, D
2010-11-01

18

Journal article

Using gene polymorphisms to assess bladder cancer risk: progress and challenges.

Kiltie, A
2012-02-01

19

Journal article

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.

Haese, A, Becker, C, Noldus, J, et al.
2000-05-01

TO TOP